Validity of the Newly Established Low-Molecular-Weight Heparin Standard in Cross-Referencing Low-Molecular-Weight Heparins
View Full Paper
Ask AI
Bookmark
Share
Key Points
This research aims to assess the validity of the WHO standard for low-molecular-weight heparins (LMWHs) in cross-referencing their efficacy and safety.
Seven LMWHs were evaluated against the WHO reference for potency using adjusted pharmacological dose-response curves.
In vitro and in vivo comparisons were conducted, focusing on anti-Xa and anti-IIa activities.
Safety and efficacy profiles linked to individual LMWH's biological characteristics were analyzed.
Cross-referencing correlated anti-Xa activity to marked elevations in anti-IIa components for some LMWHs.
Individual LMWHs demonstrated distinct safety and efficacy profiles despite similar in vitro potency.
Inappropriate cross-referencing could lead to significant dosimetric errors, increasing risk of thrombotic and bleeding complications.
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Randomized trial evaluates the safety and efficacy of LMWH preparations, suggesting a need for careful cross-referencing.